Dr. Braithwaite and the team at Signum Biosciences are working to develop the natural product, SIG1012, a minor component of coffee, for clinical application in Alzheimer's disease (AD). SIG1012 restores normal activity of an important cellular protein called PP2A (protein tyrosine phosphatase 2a). PP2A returns tau from a diseased form to its normal state, preventing the accumulation of tau into neurofibrillary tangles seen in the brain of AD patients. Signum has previously provided SIG1012 to mouse models with neurofibrillary tangles and observed a delay in onset of symptoms and decreased mortality. The studies proposed below are designed to develop SIG1012, a PP2A demethylation inhibitor present in coffee, into the clinic as rapidly and effectively as possible providing proof-of-concept for the mechanism and accelerating the availability of the compound to the Alzheimer's Disease population.